NCT07023289
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07023289
Title A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DNK


No variant requirements are available.